Initiator Pharma A/S (ST:INIT) — Market Cap & Net Worth
Market Cap & Net Worth: Initiator Pharma A/S (INIT)
Initiator Pharma A/S (ST:INIT) has a market capitalization of $16.50 Million (Skr153.33 Million) as of August 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25680 globally and #530 in its home market, demonstrating a -2.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Initiator Pharma A/S's stock price Skr2.24 by its total outstanding shares 68452892 (68.45 Million). See INIT capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Initiator Pharma A/S Market Cap History: 2017 to 2026
Initiator Pharma A/S's market capitalization history from 2017 to 2026. Data shows change from $16.41 Million to $16.50 Million (-7.13% CAGR).
Index Memberships
Initiator Pharma A/S is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.92 Billion | 0.10% | #128 of 281 |
Weight: Initiator Pharma A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Initiator Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Initiator Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INIT by Market Capitalization
Companies near Initiator Pharma A/S in the global market cap rankings as of August 5, 2026.
Key companies related to Initiator Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Initiator Pharma A/S Historical Marketcap From 2017 to 2026
Between 2017 and today, Initiator Pharma A/S's market cap moved from $16.41 Million to $ 16.50 Million, with a yearly change of -7.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr16.50 Million | -24.32% |
| 2025 | Skr21.81 Million | -56.79% |
| 2024 | Skr50.46 Million | -25.87% |
| 2023 | Skr68.07 Million | +52.48% |
| 2022 | Skr44.64 Million | -25.55% |
| 2021 | Skr59.96 Million | +82.29% |
| 2020 | Skr32.90 Million | -39.55% |
| 2019 | Skr54.42 Million | +175.43% |
| 2018 | Skr19.76 Million | +20.42% |
| 2017 | Skr16.41 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Initiator Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.50 Million USD |
| MoneyControl | $16.50 Million USD |
| MarketWatch | $16.50 Million USD |
| marketcap.company | $16.50 Million USD |
| Reuters | $16.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more